Bilix Co., Ltd.
π°π·South Korea
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)β’ Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 1
1 (50.0%)A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)
Not Applicable
Recruiting
- Conditions
- Ischemia Reperfusion InjuryCardiac Surgery Associated - Acute Kidney Injury
- Interventions
- Drug: BX-001N Experimental group 1Drug: BX-001N Experimental group 2Drug: Placebo
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Bilix Co.,Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT07164833
- Locations
- π°π·
Korea University Anam Hospital, Seoul, South Korea
π°π·Seoul National University Hospital, Seoul, South Korea
π°π·Severance Hospital, Seoul, South Korea
A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants
Phase 1
Completed
- Conditions
- Ischemia-reperfusion Injury
- Interventions
- Drug: BX-001N Part 1Drug: BX-001N Part 2Drug: Placebo
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Bilix Co.,Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT06097702
- Locations
- π¦πΊ
CMAX Clinical Research, Adelaide, South Australia, Australia
News
No news found